Clinical Trials · NCT00673387

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Name: Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Pramlintide

Phase: Phase 2
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 636
Start date: Apr 2008
Locations: 36 sites, United States
Primary endpoint: Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population

View Pramlintide compound reference